Cantor Fitzgerald Reiterates Overweight on NeuroPace, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating on NeuroPace (NASDAQ:NPCE) and maintained an $18 price target.
May 09, 2024 | 3:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating on NeuroPace, maintaining an $18 price target.
The reiteration of an Overweight rating by a prominent analyst, along with the maintenance of an $18 price target, suggests a positive outlook on NeuroPace's stock. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100